ATRA - Atara Biotherapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
South San Francisco,
United States
Type: Equity
ATRA price evolution
ATRA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.99 | $64.94 | $46.04 | $48.89 |
| Short term investments | $25.88 | $37.62 | $107.74 | $156.67 |
| Net receivables | $34.11 | $0.16 | $0.51 | $0.4 |
| Inventory | $9.71 | $6.59 | $7.86 | $5.34 |
| Total current assets | $101.87 | $118.7 | $172.32 | $224.18 |
| Long term investments | ||||
| Property, plant & equipment | $58.79 | $63.8 | $67.54 | $71 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63.63 | $70.09 | $74.12 | $77.9 |
| Total investments | $25.88 | $37.62 | $107.74 | $156.67 |
| Total assets | $165.5 | $188.79 | $246.44 | $302.08 |
| Current liabilities | ||||
| Accounts payable | $3.68 | $6.51 | $4.14 | $5.07 |
| Deferred revenue | $115.39 | $85.54 | $87.51 | $87.97 |
| Short long term debt | ||||
| Total current liabilities | $142.23 | $79.09 | $74.55 | $67.88 |
| Long term debt | $80.32 | $81.76 | $83.84 | $86.03 |
| Total noncurrent liabilities | $122.51 | $160.54 | $164.43 | $169.25 |
| Total debt | $80.32 | $81.76 | $83.84 | $86.03 |
| Total liabilities | $264.74 | $239.63 | $238.99 | $237.12 |
| Shareholders' equity | ||||
| Retained earnings | -$1969.15 | -$1908.7 | -$1838.9 | -$1767.8 |
| Other shareholder equity | -$0.2 | -$0.57 | -$0.93 | -$1.24 |
| Total shareholder equity | -$99.23 | -$50.84 | $7.45 | $64.96 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $25.99 | $93.09 | $106.28 | $200.6 |
| Short term investments | $25.88 | $149.88 | $264.98 | $300.25 |
| Net receivables | $34.11 | $40.22 | $0.99 | $1.25 |
| Inventory | $9.71 | $1.59 | ||
| Total current assets | $101.87 | $295.08 | $384.62 | $523.27 |
| Long term investments | $1.2 | $1.2 | ||
| Property, plant & equipment | $58.79 | $74.32 | $79.94 | $62.82 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $63.63 | $81.34 | $83.51 | $64.85 |
| Total investments | $25.88 | $149.88 | $266.18 | $301.45 |
| Total assets | $165.5 | $376.42 | $468.13 | $588.12 |
| Current liabilities | ||||
| Accounts payable | $3.68 | $6.87 | $17.37 | $7.12 |
| Deferred revenue | $115.39 | $85 | $96.47 | $61.25 |
| Short long term debt | ||||
| Total current liabilities | $142.23 | $78.92 | $105.79 | $82.9 |
| Long term debt | $80.32 | $3.64 | $25.52 | $13.04 |
| Total noncurrent liabilities | $122.51 | $170.86 | $82.73 | $42.88 |
| Total debt | $80.32 | $88.3 | $25.52 | $13.04 |
| Total liabilities | $264.74 | $249.78 | $188.51 | $125.78 |
| Shareholders' equity | ||||
| Retained earnings | -$1969.15 | -$1693.02 | -$1464.72 | -$1124.58 |
| Other shareholder equity | -$0.2 | -$2.07 | -$0.37 | $0.3 |
| Total shareholder equity | -$99.23 | $126.64 | $279.61 | $462.34 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.25 | $2.14 | $0.96 | $1.23 |
| Cost of revenue | $3.16 | $2.62 | $2.9 | $0.22 |
| Gross Profit | $1.09 | -$0.48 | -$1.94 | $1.01 |
| Operating activities | ||||
| Research & development | $49.6 | $56.89 | $56.14 | $62.16 |
| Selling, general & administrative | $11.45 | $12.25 | $13.34 | $13.87 |
| Total operating expenses | $61.05 | $69.14 | $69.48 | $76.03 |
| Operating income | -$59.96 | -$69.61 | -$71.41 | -$75.02 |
| Income from continuing operations | ||||
| EBIT | -$59.26 | -$68.42 | -$69.73 | -$73.41 |
| Income tax expense | $0.01 | -$0.02 | $0 | $0.02 |
| Interest expense | $1.18 | $1.4 | $1.38 | $1.34 |
| Net income | ||||
| Net income | -$60.45 | -$69.8 | -$71.11 | -$74.77 |
| Income (for common shares) | -$60.45 | -$69.8 | -$71.11 | -$74.77 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $8.57 | $63.57 | $20.34 | |
| Cost of revenue | $8.89 | |||
| Gross Profit | -$0.31 | $63.57 | $20.34 | |
| Operating activities | ||||
| Research & development | $224.78 | $272.53 | $282 | $244.65 |
| Selling, general & administrative | $50.91 | $71.55 | $78.8 | $64.4 |
| Total operating expenses | $275.69 | $344.09 | $360.8 | $309.05 |
| Operating income | -$276.01 | -$280.51 | -$340.46 | -$309.05 |
| Income from continuing operations | ||||
| EBIT | -$270.83 | -$230.28 | -$340.1 | -$306.61 |
| Income tax expense | $0.01 | $0.01 | $0.05 | $0.01 |
| Interest expense | $5.29 | -$1.99 | ||
| Net income | ||||
| Net income | -$276.13 | -$228.3 | -$340.14 | -$306.62 |
| Income (for common shares) | -$276.13 | -$228.3 | -$340.14 | -$306.62 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$60.45 | -$69.8 | -$71.11 | -$74.77 |
| Operating activities | ||||
| Depreciation | $4.15 | $4.23 | $4.15 | $4.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $9.93 | $11.14 | $12.55 | $11.76 |
| Total cash flows from operations | -$50.41 | -$51.35 | -$52.8 | -$38.43 |
| Investing activities | ||||
| Capital expenditures | -$0.04 | -$0.26 | -$0.5 | -$0.4 |
| Investments | $9.99 | $70.7 | $49.98 | -$5.61 |
| Total cash flows from investing | $9.94 | $70.45 | $49.48 | -$6.01 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.55 | -$0.05 | $0.64 | |
| Net borrowings | -$0.21 | -$0.21 | -$0.21 | -$0.31 |
| Total cash flows from financing | $1.51 | -$0.21 | $0.47 | $0.23 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$38.95 | $18.89 | -$2.84 | -$44.2 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$276.13 | -$228.3 | -$340.14 | -$306.62 |
| Operating activities | ||||
| Depreciation | $16.62 | $14.57 | $11.29 | $9.79 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $45.39 | $53.84 | $53.87 | $51.35 |
| Total cash flows from operations | -$192.98 | -$270.43 | -$220.52 | -$180.76 |
| Investing activities | ||||
| Capital expenditures | -$1.2 | $90.57 | -$10.58 | -$4.51 |
| Investments | $125.06 | $112.38 | $32.84 | -$116.22 |
| Total cash flows from investing | $123.87 | $202.96 | $22.26 | -$120.73 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2.14 | $21.89 | $98.7 | $422.97 |
| Net borrowings | -$0.95 | $30.09 | -$0.25 | -$0.39 |
| Total cash flows from financing | $2.01 | $53.08 | $103.94 | $427.57 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$67.1 | -$14.39 | -$94.32 | $126.09 |
News
Fundamentals
| Market cap | $74.51M |
|---|---|
| Enterprise value | $128.84M |
| Shares outstanding | 106.45M |
| Revenue | $8.57M |
|---|---|
| EBITDA | -$254.20M |
| EBIT | -$270.83M |
| Net Income | -$276.13M |
| Revenue Q/Q | 1.82K% |
| Revenue Y/Y | -86.51% |
| P/E ratio | -0.27 |
|---|---|
| EV/Sales | 15.03 |
| EV/EBITDA | -0.51 |
| EV/EBIT | -0.48 |
| P/S ratio | 8.69 |
| P/B ratio | -0.75 |
| Book/Share | -0.93 |
| Cash/Share | 0.24 |
| EPS | -$2.59 |
|---|---|
| ROA | -122.34% |
| ROE | 1.42K% |
| Debt/Equity | -2.67 |
|---|---|
| Net debt/EBITDA | -0.94 |
| Current ratio | 0.72 |
| Quick ratio | 0.65 |